Skip to main content

Advertisement

SpringerLink
Log in

Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson’s disease in Chinese patients

  • Original article
  • Published:
Acta Neurologica Belgica Aims and scope Submit manuscript

Abstract

Purpose

Parkinson’s disease (PD) is a neurodegenerative disease that usually leads to memory impairment, cognitive decline and dementia. Previous studies have reported that plasminogen activator inhibitor-1 (PAI-1) gene polymorphisms play important roles in cardiovascular diseases, obesity, inflammation and other diseases. However, the role of PAI-1 in the diagnosis of Parkinson's disease has not been reported so far.

Methods

This study was a case–control study. This study included 131 PD patients and 97 healthy volunteers. polymerase chain reaction-restriction fragment length polymorphism (PCR–RFLP) was used to analyze the polymorphic loci of five different regions in PAI-1 gene (rs2227631, rs1799889, rs6092, rs2227694 and rs7242). 60 PD patients and 60 healthy volunteers were selected to detect the plasma PAI-1 concentration. The allele and genotype frequencies of SNPs were assessed using the SHEsis program.

Results

We found that GG genotype frequency and G allele frequency of rs2227631 was significantly higher in the PD patients. Statistically significant difference for rs1799889 could be observed in overdominant model. In subgroup analysis, a significant difference in genotype frequency distribution and allele frequency was found for rs2227631 and rs1799889 between early-onset PD group and the control group. For cognitive dysfunction, the subcomponent showed that GG genotype frequency and G allele frequency of rs2227631 was significantly higher in normal cognition group. The codominant model of rs1799889 was significantly different between the cognitive impairment group and the control group. In addition, the expression of PAI-1 in plasma of PD patients was significantly higher than that of controls, and further analysis showed that the expression of PAI-1 in patients with cognitive impairment was significantly higher than that in patients with cognitive normal.

Conclusion

Our results indicate that the PAI-1 gene rs2227631 and rs1799889 polymorphisms were significantly associated with PD susceptibility in the Chinese Han population. PAI-1 has the potential to become a new therapeutic target and diagnostic marker.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Availability of data and material

The data used to support the findings of this study are available from the corresponding author upon reasonable request.

Code availability

Not applicable.

References

  1. Tysnes OB, Storstein A (2017) Epidemiology of Parkinson’s disease. J Neural Transm (Vienna) 124(8):901–905

    Article  PubMed  Google Scholar 

  2. Stoker TB, Barker RA (2020) Recent developments in the treatment of Parkinson’s disease. F1000Res 9(Faculty Rev):862

  3. Burbulla LF, Kruger R (2011) Converging environmental and genetic pathways in the pathogenesis of Parkinson’s disease. J Neurol Sci 306(1–2):1–8

    Article  CAS  PubMed  Google Scholar 

  4. Kim KS et al (2012) Proteolytic cleavage of extracellular alpha-synuclein by plasmin: implications for Parkinson disease. J Biol Chem 287(30):24862–24872

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Park SM, Kim KS (2013) Proteolytic clearance of extracellular alpha-synuclein as a new therapeutic approach against Parkinson disease. Prion 7(2):121–126

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gorska-Ciebiada M et al (2016) Plasma levels of thrombomodulin, plasminogen activator inhibitor-1 and fibrinogen in elderly, diabetic patients with depressive symptoms. Aging Clin Exp Res 28(5):843–851

    Article  PubMed  Google Scholar 

  7. Dellas C, Loskutoff DJ (2005) Historical analysis of PAI-1 from its discovery to its potential role in cell motility and disease. Thromb Haemost 93(4):631–640

    Article  CAS  PubMed  Google Scholar 

  8. Palmirotta R et al (2009) Prognostic value of pre-surgical plasma PAI-1 (plasminogen activator inhibitor-1) levels in breast cancer. Thromb Res 124(4):403–408

    Article  CAS  PubMed  Google Scholar 

  9. Ahn MY et al (1999) Endogenous plasminogen activator expression after embolic focal cerebral ischemia in mice. Brain Res 837(1–2):169–176

    Article  CAS  PubMed  Google Scholar 

  10. Pan H et al (2018) Role of plasminogen activator inhibitor-1 in the diagnosis and prognosis of patients with Parkinson’s disease. Exp Ther Med 15(6):5517–5522

    PubMed  PubMed Central  Google Scholar 

  11. Reuland CJ, Church FC (2020) Synergy between plasminogen activator inhibitor-1, alpha-synuclein, and neuroinflammation in Parkinson’s disease. Med Hypotheses 138:109602

    Article  CAS  PubMed  Google Scholar 

  12. Zhang Q et al (2020) Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphisms and risk of venous thromboembolism—a meta-analysis and systematic review. Vasa 49(2):141–146

    Article  PubMed  Google Scholar 

  13. Huang X et al (2014) Pai-1 gene variants and COC use are associated with stroke risk: a case-control study in the Han Chinese women. J Mol Neurosci 54(4):803–810

    Article  CAS  PubMed  Google Scholar 

  14. Roncal C et al (2004) Influence of the 4G/5G PAI-1 genotype on angiotensin II-stimulated human endothelial cells and in patients with hypertension. Cardiovasc Res 63(1):176–185

    Article  CAS  PubMed  Google Scholar 

  15. Joutsa J et al (2014) Diagnostic accuracy of Parkinsonism syndromes by general neurologists. Parkinsonism Relat Disord 20(8):840–844

    Article  PubMed  Google Scholar 

  16. Pelletier S et al (2016) Investigation of cognitive improvement in alcohol-dependent inpatients using the Montreal Cognitive Assessment (MoCA) score. J Addict 2016:1539096

    PubMed  PubMed Central  Google Scholar 

  17. Titze-de-Almeida R, Titze-de-Almeida SS (2018) miR-7 replacement therapy in Parkinson’s disease. Curr Gene Ther 18(3):143–153

    Article  CAS  PubMed  Google Scholar 

  18. Rahman FA, Krause MP (2020) PAI-1, the plasminogen system, and skeletal muscle. Int J Mol Sci 21(19):7066

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. Elmi S et al (2019) Role of tissue plasminogen activator and plasminogen activator inhibitor as potential biomarkers in psychosis. Asian J Psychiatr 43:105–110

    Article  PubMed  Google Scholar 

  20. Balsara RD, Ploplis VA (2008) Plasminogen activator inhibitor-1: the double-edged sword in apoptosis. Thromb Haemost 100(6):1029–1036

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  21. Samarakoon R et al (2019) The TGF-beta1/p53/PAI-1 signaling axis in vascular senescence: role of caveolin-1. Biomolecules 9(8):341

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Aso Y (2007) Plasminogen activator inhibitor (PAI)-1 in vascular inflammation and thrombosis. Front Biosci 12:2957–2966

    Article  CAS  PubMed  Google Scholar 

  23. Jayakumar AR, Apeksha A, Norenberg MD (2017) Role of matricellular proteins in disorders of the central nervous system. Neurochem Res 42(3):858–875

    Article  CAS  PubMed  Google Scholar 

  24. Flores-Dorantes MT, Diaz-Lopez YE, Gutierrez-Aguilar R (2020) Environment and gene association with obesity and their impact on neurodegenerative and neurodevelopmental diseases. Front Neurosci 14:863

    Article  PubMed  PubMed Central  Google Scholar 

  25. Arnoldussen IA, Kiliaan AJ, Gustafson DR (2014) Obesity and dementia: adipokines interact with the brain. Eur Neuropsychopharmacol 24(12):1982–1999

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Liu Y et al (2018) The roles of PAI-1 gene polymorphisms in atherosclerotic diseases: a systematic review and meta-analysis involving 149,908 subjects. Gene 673:167–173

    Article  CAS  PubMed  Google Scholar 

  27. Alexa D et al (2014) Parkinson’s disease and carotid intima-media thickness. Rev Med Chir Soc Med Nat Iasi 118(1):52–56

    CAS  PubMed  Google Scholar 

  28. Tsai SJ et al (2008) Plasminogen activator inhibitor-1 gene is associated with major depression and antidepressant treatment response. Pharmacogenet Genom 18(10):869–875

    Article  CAS  Google Scholar 

  29. Yenilmez C et al (2017) A study of the possible association of plasminogen activator inhibitor type 1 4G/5G insertion/deletion polymorphism with susceptibility to schizophrenia and in its subtypes. J Clin Pharm Ther 42(1):103–107

    Article  CAS  PubMed  Google Scholar 

  30. de Lau LM, Breteler MM (2006) Epidemiology of Parkinson’s disease. Lancet Neurol 5(6):525–535

    Article  PubMed  Google Scholar 

  31. Gibb WR, Lees AJ (1988) A comparison of clinical and pathological features of young- and old-onset Parkinson’s disease. Neurology 38(9):1402–1406

    Article  CAS  PubMed  Google Scholar 

  32. Schrag A, Schott JM (2006) Epidemiological, clinical, and genetic characteristics of early-onset Parkinsonism. Lancet Neurol 5(4):355–363

    Article  CAS  PubMed  Google Scholar 

  33. Osmak GJ et al (2020) Age-dependent approach to search for genetic variants associated with myocardial infarction. Mol Biol (Mosk) 54(4):699–704

    Article  CAS  PubMed  Google Scholar 

  34. Svenningsson P et al (2012) Cognitive impairment in patients with Parkinson’s disease: diagnosis, biomarkers, and treatment. Lancet Neurol 11(8):697–707

    Article  PubMed  Google Scholar 

  35. Wang J et al (2018) Association between plasma levels of PAI-1, tPA/PAI-1 molar ratio, and mild cognitive impairment in Chinese patients with type 2 diabetes mellitus. J Alzheimers Dis 63(2):835–845

    Article  CAS  PubMed  Google Scholar 

  36. Li X et al (2016) Regulatory role of microRNA-30b and plasminogen activator inhibitor-1 in the pathogenesis of cognitive impairment. Exp Ther Med 11(5):1993–1998

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Acknowledgements

Not applicable.

Funding

This work was supported by the Basic Research Project of Zhejiang Provincial Department of Science and Technology (2018C37132), the Key Provincial Ministry Joint Construction Program of Zhejiang Provincial Health Commission (WKJ-ZJ-1809).

Author information

Author notes

  1. The authors equally contributed: Qi Xu and Qilun Lai.

Authors and Affiliations

  1. Department of Radiology, Zhejiang Hospital, Hangzhou, 310000, China

    Qi Xu

  2. Department of Neurology, Zhejiang Hospital, Hangzhou, 310000, China

    Qilun Lai, Junjun Wang, Liying Zhuang, Lin Cheng, Yejia Mo, Lu Liu, Zexian Zhao & Song Qiao

  3. Department of Neurology, Second Affiliated Hospital of Zhejiang University, Hangzhou, 310000, China

    Ying Zhang

  4. The Second Clinical Medical College, Zhejiang Chinese Medicine University, Hangzhou, 310000, China

    Shiting Weng

Authors
  1. Qi Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Qilun Lai
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Junjun Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Liying Zhuang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Lin Cheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yejia Mo
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Lu Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Zexian Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Ying Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Shiting Weng
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Song Qiao
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

QX and SQ conceived and designed the experiments and revised the manuscript. QL, JW, LZ, LC and YM did genetic analyzes and collected the clinical data. LL, ZZ, YZ and SW analyzed and interpreted the data; and drafted the manuscript. All authors were involved in the revision of the manuscript.

Corresponding author

Correspondence to Song Qiao.

Ethics declarations

Conflict of interest

All authors report no declarations of interest.

Ethics approval

The study was designed and performed in agreement with the Declaration of Helsinki and was approved by Medical Ethics Committee of Zhejiang Hospital (Approval number: 2018(14K)). Written informed consent was obtained from individual or guardian participants.

Consent to participate

Not applicable.

Consent for publication

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary Information

Below is the link to the electronic supplementary material.

Supplementary file1 (DOCX 16 KB)

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Xu, Q., Lai, Q., Wang, J. et al. Association between plasminogen activator inhibitor-1 gene polymorphisms and susceptibility to Parkinson’s disease in Chinese patients. Acta Neurol Belg 122, 1557–1566 (2022). https://doi.org/10.1007/s13760-021-01843-7

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13760-021-01843-7

Keywords

Search

Navigation